（记者 王瀚黎） 截至发稿，中恒集团市值为88亿元。 每经头条（nbdtoutiao）——实施城乡居民增收计划、降准降息等工具灵活高效运用、增加普通高中学 位……深度解读中央经济工作会议 每经AI快讯，中恒集团（SH 600252，收盘价：2.76元）12月12日晚间发布公告称，公司第十届第三十 四次董事会会议于2025年12月12日在广西南宁市江南区高岭路100号办公楼会议室召开。会议审议了 《广西梧州中恒集团股份有限公司关于取消监事会并修订 <广西梧州中恒集团股份有限公司章程> 及其 附件的议案》等文件。 2024年1至12月份，中恒集团的营业收入构成为：医药制造业占比76.26%，其他业务占比13.84%，食品 占比9.9%。 ...

Group 1 - The core point of the article is that Frontier Bio (SH 688221) announced a board meeting to discuss the granting of reserved restricted stocks under the 2025 restricted stock incentive plan [1] - For the year 2024, Frontier Bio's revenue composition is 97.13% from the pharmaceutical manufacturing industry and 2.87% from other businesses [1] - As of the report date, Frontier Bio has a market capitalization of 7.6 billion yuan [1]

售;机械设备研发;企业管理;企业管理咨询。 (除依法须经批准的项目外,凭营业执照依法自主开展经营活动) 上海复瑞益企业咨询管理合伙企业（有限合伙） 器 每经AI快讯，天眼查App显示，近日，复星凯瑞(上海)生物科技有限公司发生工商变更，新增深圳市鹏复生物医药产业私募股权投资基金合伙企业(有限合 伙)、深圳市坪山区引导基金投资有限公司、上海复瑞益企业咨询管理合伙企业(有限合伙)为股东，同时，注册资本由约19.2亿元人民币增至约22.3亿元人民 币，增幅约16%。复星凯瑞(上海)生物科技有限公司成立于2017年4月，法定代表人为WenjieZhang，经营范围含药品生产、药品委托生产、药品进出口、医 学研究和试验发展、细胞技术研发和应用、人体基因诊断与治疗技术开发、人体干细胞技术开发和应用等。股东信息显示，该公司由上海复星医药 （600196）产业发展有限公司、上海复瑞生企业咨询管理合伙企业(有限合伙)及上述新增股东共同持股。 | | 都在用的商业查询工具 | 查公司 查老板 查关系 音风险 | | --- | --- | --- | | | 国家中小企业发展子基金旗下机构 | 复星凯瑞（上海）生物科技有限公司 ...

Investment Rating - The report assigns an "Accumulate" rating for the company for the first time [1] Core Views - The company has undergone a strategic transformation from a single focus on orthopedics to multiple therapeutic areas including cardiovascular, nutritional supplements, and electrolyte regulation. The core strategy is centered around "product supremacy" through a "self-research + collaboration" model to enrich the product pipeline [6][14] - In the first half of 2025, the company achieved revenue of 1.0995 billion yuan, with nutritional drugs contributing 43.88% and cardiovascular drugs 27.99% to total revenue. The company has a stable shareholding structure with Shen Zhenyu as the actual controller [6][14] - The company has shown a gradual recovery in performance, with a net profit of 244 million yuan in Q3 2025, representing a year-on-year growth of 32.85%, establishing a healthy operating pattern characterized by low debt and high profitability resilience [6][14] Financial Performance - The company’s projected revenues for 2025-2027 are 2,252.80 million, 2,392.24 million, and 2,637.93 million yuan, with growth rates of -7.70%, 6.19%, and 10.27% respectively. The projected net profits for the same period are 254.40 million, 288.74 million, and 348.65 million yuan, with growth rates of 9.30%, 13.50%, and 20.75% respectively [7] - The current market capitalization corresponds to a PE ratio of 28.25 for 2025, 24.89 for 2026, and 20.61 for 2027, indicating a favorable valuation outlook as the company navigates the pressures of centralized procurement [6][7] Industry Analysis - The global pharmaceutical market is expected to reach 1.9 trillion USD by 2027, with China's market share anticipated to continue increasing. Innovative drug technologies such as ADC, bispecific antibodies, and CGT are projected to be core growth engines [6][14] - The industry is currently in a dual-track development phase characterized by the normalization of centralized procurement and supportive policies for innovative drugs. The company’s core products have a high market share and align well with industry trends, indicating strong adaptability [6][14]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688189 证券简称：南新制药 公告编号：2025-053 湖南南新制药股份有限公司 关于聘任2025年度审计机构 暨变更会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 拟聘任的会计师事务所名称：华兴会计师事务所（特殊普通合伙）（以下简称"华兴"）。 ● 原聘任的会计师事务所名称：大华会计师事务所（特殊普通合伙）（以下简称"大华"）。 ● 变更会计师事务所的简要原因及前任会计师的异议情况：为确保湖南南新制药股份有限公司（以下简 称"公司"）2025年度财务报告审计、内部控制审计工作的顺利开展，参照财政部、国务院国资委及证监 会联合发布的《国有企业、上市公司选聘会计师事务所管理办法》的相关规定，结合公司业务发展情况 和审计服务需求，公司拟聘任华兴担任公司2025年度审计机构，负责公司2025年度财务审计及内部控制 审计工作。公司就本次变更会计师事务所事项与大华、华兴进行了充分沟通，取得了其理解和支持，双 方均已明确知悉本事项 ...

Group 1 - The core point of the article is that Zhongheng Group has reported a guarantee balance of approximately 369 million yuan, which accounts for 6.12% of the company's audited net assets for 2024 [1] - As of the announcement date, Zhongheng Group's market capitalization is 9.1 billion yuan [1] - The revenue composition for Zhongheng Group in 2024 is as follows: 76.26% from pharmaceutical manufacturing, 13.84% from other businesses, and 9.9% from food [1]

Group 1 - The core point of the article is that Zhongheng Group announced the receipt of two medical device registration certificates for its subsidiary, Hainan Laimei Medical Equipment Co., Ltd., from the Hainan Provincial Drug Administration, including a "medical electronic endoscope image processor" [1] - For the fiscal year 2024, Zhongheng Group's revenue composition is as follows: 76.26% from pharmaceutical manufacturing, 13.84% from other businesses, and 9.9% from food [1] - As of the report date, Zhongheng Group has a market capitalization of 9.1 billion yuan [1]

Group 1 - Yunnan Baiyao has undergone significant management changes, with Dong Ming stepping down as the legal representative and Wang Minghui resigning as chairman, replaced by Zhang Wenxue [1][2] - The registered capital of Yunnan Baiyao has increased from approximately 1.04 billion RMB to about 1.78 billion RMB [1][2] - The company was established in November 1993 and operates in various sectors including chemical raw materials, traditional Chinese medicine, and medical devices [1][3] Group 2 - The company is jointly held by Yunnan Provincial State-owned Assets Management Company, Xinhua Duhua Industrial Group Co., Ltd., and Yunnan Hehe Group Co., Ltd. [1][4] - The 11th Board of Directors meeting announced Zhang Wenxue as chairman and Dong Ming as vice chairman for a term of three years [1][2] - The company has a diverse business scope that includes sales of pharmaceuticals, medical devices, and technology consulting services [1][3]

每经AI快讯，益方生物（SH 688382，收盘价：28.19元）12月9日晚间发布公告称，公司第二届2025年 第八次董事会会议于2025年12月8日以现场结合通讯形式召开。会议审议了《关于提请召开公司2025年 第二次临时股东会的议案》等文件。 （记者 贾运可） 2024年1至12月份，益方生物的营业收入构成为：医药制造业占比100.0%。 截至发稿，益方生物市值为163亿元。 每经头条（nbdtoutiao）——处方药变"瘾品"：国内首次报告普瑞巴林滥用致成瘾病例，网络平台暴 露"无病历可购药"漏洞，列管与否尚需科学考量 ...

每经头条（nbdtoutiao）——处方药变"瘾品"：国内首次报告普瑞巴林滥用致成瘾病例，网络平台暴 露"无病历可购药"漏洞，列管与否尚需科学考量 每经AI快讯，信立泰（SZ 002294，收盘价：61.1元）12月9日晚间发布公告称，公司第六届第十五次董 事会会议于2025年12月9日以书面方式召开。会议审议了《关于修订、制定和废止公司部分治理制度的 议案》等文件。 2025年1至6月份，信立泰的营业收入构成为：医药制造业占比91.46%，医疗器械占比8.54%。 截至发稿，信立泰市值为681亿元。 （记者 王瀚黎） ...